Key result
Biotherapies including adult stem cells and bone marrow-derived endothelial cell progenitors are under investigation for secondary prevention of left ventricular dysfunction after myocardial infarction.
Biotherapies such as stem cells and biomaterials are being investigated to prevent left ventricular remodeling and heart failure after acute myocardial infarction.
Treatment of acute myocardial infarction in the future should focus not only on improving acute treatment, as it has been done over the past decades, but also on secondary prevention of left ventricular dysfunction and/or progression to heart failure by preserving left ventricular shape, avoiding left ventricular remodeling and stimulating cardiac regeneration. Biotherapies with adult stem cells and bone marrow-derived endothelial cell progenitors, combined or not with biomaterials, and new drugs are under investigation and will probably be part of routine clinical practice for patients suffering from myocardial infarction in the near future.
No takes yet. Share an insight, caveat, or question.
Jérôme Roncalli (2014) conducted a review in Acute Myocardial Infarction. Biotherapies (adult stem cells, bone marrow-derived endothelial cell progenitors, biomaterials) was evaluated. Biotherapies including adult stem cells and bone marrow-derived endothelial cell progenitors are under investigation for secondary prevention of left ventricular dysfunction after myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: